Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex autoimmune disorder driven by an interplay of immune cells, orbital fibroblasts and tissue remodelling factors that lead to inflammation, oedema and, ultimately, potential vision loss.1 While the disease ...

Dr Linda Siminerio, a leading expert in diabetes education and healthcare delivery, shares insights from her distinguished career. Inspired by her father’s type 1 diabetes diagnosis, she has dedicated her work to improving patient education and care models. She emphasizes the importance of a team-based approach and staying ahead of technological advancements. With AI and machine learning already influencing diabetes management, she urges healthcare providers to adapt and engage with these innovations. Through her contributions, Dr Siminerio continues to shape the future of diabetes care, ensuring that patients receive the education and support they need.

Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...

This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained ...

Polycystic ovary syndrome (PCOS) is a multifactorial, multifaceted syndrome that affects women across all ages from adolescence to post-menopause. It is reported to be the most common endocrinopathy in women of the reproductive age group.1 The nature of this syndrome ...

‘Closed-loop’ systems mark a significant advancement in managing type 1 diabetes. These systems which continuously monitor glucose levels and automatically deliver insulin through a pump, help many individuals with type 1 diabetes maintain optimal glucose levels with greater ease. In this episode, we explore the progress, challenges and impact of these innovative technologies with Endocrinology Clinical Pharmacy Specialist, Dr Diana Isaacs, and highlight their future potential.

Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...

During more than 30 years of clinical practice as a gynaecologist, I have observed that very few novel medications have had a significant impact in the field of women’s health. There have been additions to selective oestrogen receptor modulators (SERMs), ...

Worldwide prevalence of type 2 diabetes mellitus (T2DM) is steadily increasing due to rising levels of obesity over the past 40 years caused by sedentary lifestyles and unhealthy eating habits. Diabetes now ranks ninth among the top ten causes of death ...